XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Schedule of reportable business segment information
Reportable business segment information for the years ended December 31, 2021 and 2020 is as follows (dollar amounts in thousands):
Year Ended December 31,20212020
Net sales:  
Asia$176,860 $138,717 
Europe91,539 77,688 
North America149,746 145,481 
Latin America and Other25,939 23,319 
Total net sales444,084 385,205 
Contribution margin (1):  
Asia89,939 66,801 
Europe30,959 26,014 
North America56,922 50,193 
Latin America and Other10,953 9,771 
Total contribution margin188,773 152,779 
Selling, general and administrative (2)154,103 131,297 
Operating income34,670 21,482 
Other income (loss), net(2,848)1,339 
Income before provision for income taxes$31,822 $22,821 
___________________________
(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
(2)  Service fees in China totaled $18.7 million and $11.7 million for the years ended December 31, 2021 and 2020, respectively. These service fees are included in our selling, general and administrative expenses.
Year Ended December 31,20212020
Capital expenditures:  
Asia$1,081 $542 
Europe142 34 
North America5,371 4,267 
Latin America and Other72 62 
Total capital expenditures$6,666 $4,905 
Depreciation and amortization:  
Asia$1,825 $1,919 
Europe64 77 
North America9,206 8,673 
Latin America and Other67 74 
Total depreciation and amortization$11,162 $10,743 

As of December 31,20212020
Assets:  
Asia$104,659 $82,572 
Europe15,486 16,398 
North America131,207 142,324 
Latin America and Other7,522 8,204 
Total assets$258,874 $249,498 
Schedule of consolidated net sales revenue by geographical locations From an individual country perspective, only the United States and South Korea comprise approximately 10 percent or more of consolidated net sales for the years ended December 31, 2021 and 2020 as follows (dollar amounts in thousands):
Year Ended December 31,20212020
Net sales:  
United States$138,174 $134,976 
South Korea61,107 62,041 
Other244,803 188,188 
Total net sales$444,084 $385,205 
Schedule of revenue generated by each of the Company's product lines Revenue generated by each of our product lines is set forth below (dollars in thousands):
Year Ended December 31,20212020
Asia:  
General health$50,044 $36,445 
Immunity1,599 847 
Cardiovascular48,019 40,496 
Digestive36,069 32,605 
Personal care17,765 10,606 
Weight management23,364 17,718 
 176,860 138,717 
Europe:  
General health$40,045 $32,822 
Immunity8,957 8,231 
Cardiovascular11,787 10,863 
Digestive23,142 18,673 
Personal care5,149 4,663 
Weight management2,459 2,436 
 91,539 77,688 
North America:  
General health$65,379 $61,897 
Immunity19,563 23,036 
Cardiovascular16,219 15,852 
Digestive37,130 32,851 
Personal care7,579 7,587 
Weight management3,876 4,258 
 149,746 145,481 
Latin America and Other:  
General health$7,532 $6,867 
Immunity2,667 3,122 
Cardiovascular2,001 1,512 
Digestive10,291 9,863 
Personal care2,573 1,203 
Weight management875 752 
 25,939 23,319 
Total net sales$444,084 $385,205 
Schedule of consolidated property, plant and equipment by geographical locations From an individual country perspective, only the United States comprise 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
As of December 31 20212020
Property, plant and equipment, net  
United States$46,595 $50,025 
Other4,262 4,330 
Total property, plant and equipment$50,857 $54,355